The role of p38 mapk in the aetiopathogenesis of psoriasis and psoriatic arthritis

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Mavropoulos, Athanasios ^a,b   Rigopoulou, Eirini I ^c   Liaskos, Christos ^a   Bogdanos, Dimitrios P ^a,b,c   Sakkas, Lazaros I ^c,d,e  

^a Cellular Immunotherapy and Molecular Immunodiagnostics   (Greece)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF THESSALY   (Greece)

^d OLD DOMINION UNIVERSITY   (United States)

^e UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; APOPTOSIS; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SYNOVIUM; TH17 CELL; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ARTHRITIS, PSORIATIC; HUMANS; IMMUNITY, INNATE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 84885346869     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/569751     Document Type: Review

References (111)

1. Lowes M. A., Bowcock A. M., Krueger J. G., Pathogenesis and therapy of psoriasis. Nature 2007 445 7130 866 873 2-s2.0-33847279025 10.1038/nature05663
2. Nestle F. O., Kaplan D. H., Barker J., Mechanisms of disease: psoriasis. New England Journal of Medicine 2009 361 5 444 509 2-s2.0-68049131637 10.1056/NEJMra0804595
3. Krueger G., Ellis C. N., Psoriasis-recent advances in understanding its pathogenesis and treatment. Journal of the American Academy of Dermatology 2005 53 1, supplement S94 S100 2-s2.0-20444497652 10.1016/j.jaad.2005.04.035 (Pubitemid 40828186)
4. Bos J. D., De Rie M. A., Teunissen M. B. M., Piskin G., Psoriasis: dysregulation of innate immunity. British Journal of Dermatology 2005 152 6 1098 1107 2-s2.0-21644455704 10.1111/j.1365-2133.2005.06645.x (Pubitemid 40933406)
5. Gladman D. D., Antoni C., Mease P., Clegg D. O., Nash O., Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases 2005 64 2 ii14 ii17 2-s2.0-14244260176 10.1136/ard.2004. 032482 (Pubitemid 40288513)
6. Boehncke W. H., Menter A., Burden of disease: psoriasis and psoriatic arthritis. American Journal of Clinical Dermatology 2013
7. Mak R. K. H., Hundhausen C., Nestle F. O., Progress in understanding the immunopathogenesis of psoriasis. Actas Dermo-Sifiliograficas 2009 100 2 2 13 2-s2.0-76749141832 10.1016/S0001-7310(09)73372-1
8. Veale D. J., Ritchlin C., FitzGerald O., Immunopathology of psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases 2005 64 2, supplement ii26 ii29 2-s2.0-14244250311 10.1136/ard.2004.031740 (Pubitemid 40288516)
9. Bachelez H., Immunopathogenesis of psoriasis: recent insights on the role of adaptive and innate immunity. Journal of Autoimmunity 2005 25, supplement 69 73 2-s2.0-28444493712 10.1016/j.jaut.2005.09.025 (Pubitemid 41728048)
10. Villanova F., Di Meglio P., Nestle F. O., Biomarkers in psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases 2013 72, supplement 2 104 110
11. Ottaviani C., Nasorri F., Bedini C., de Pità O., Girolomoni G., Cavani A., CD56brightCD16- NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. European Journal of Immunology 2006 36 1 118 128 2-s2.0-30944461598 10.1002/eji.200535243 (Pubitemid 43116398)
12. Peternel S., Kaštelan M., Immunopathogenesis of psoriasis: focus on natural killer T cells. Journal of the European Academy of Dermatology and Venereology 2009 23 10 1123 1127 2-s2.0-70349122542 10.1111/j.1468-3083.2009. 03292.x
13. Kagami S., Rizzo H. L., Lee J. J., Koguchi Y., Blauvelt A., Circulating Th17, Th22, and Th1 cells are increased in psoriasis. Journal of Investigative Dermatology 2010 130 5 1373 1383 2-s2.0-77951091571 10.1038/jid.2009.399
14. Fuentes-Duculan J., Suárez-Farĩas M., Zaba L. C., Nograles K. E., Pierson K. C., Mitsui H., Pensabene C. A., Kzhyshkowska J., Krueger J. G., Lowes M. A., A subpopulation of CD163-positive macrophages is classically activated in psoriasis. Journal of Investigative Dermatology 2010 130 10 2412 2422 2-s2.0-77956878373 10.1038/jid.2010.165
15. Tobin A. M., Lynch L., Kirby B., O'Farrelly C., Natural killer cells in psoriasis. Journal of Innate Immunity 2011 3 4 403 410 2-s2.0-80955180091 10.1159/000328011
16. Farkas A., Kemeny L., Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: new pieces in the puzzle. International Immunopharmacology 2012 13 2 215 218
17. + T cell population in psoriatic lesions. Clinical & Experimental Immunology 2013 173 1 38 46
18. Leong T. T., Fearon U., Veale D. J., Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Current Rheumatology Reports 2005 7 4 325 329 2-s2.0-27244449951
19. Maeda S., Hayami Y., Naniwa T., Ueda R., The Th17/IL-23 axis and natural immunity in psoriatic arthritis. International Journal of Rheumatology 2012 2012 8 539683 10.1155/2012/539683
20. Johansen C., Kragballe K., Westergaard M., Henningsen J., Kristiansen K., Iversen L., The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. British Journal of Dermatology 2005 152 1 37 42 2-s2.0-13244284850 10.1111/j.1365-2133.2004.06304.x
21. Yu X.-J., Li C.-Y., Dai H.-Y., Cai D.-X., Wang K.-Y., Xu Y.-H., Chen L.-M., Zhou C.-L., Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Experimental and Molecular Pathology 2007 83 3 413 418 2-s2.0-36148934536 10.1016/j.yexmp.2007. 05.002 (Pubitemid 350103561)
22. Wang S., Uchi H., Hayashida S., Urabe K., Moroi Y., Furue M., Differential expression of phosphorylated extracellular signal-regulated kinase 1/2, phosphorylated p38 mitogen-activated protein kinase and nuclear factor- B p105/p50 in chronic inflammatory skin diseases. Journal of Dermatology 2009 36 10 534 540 2-s2.0-70349615633 10.1111/j.1346-8138.2009.00696.x
23. Arthur J. S. C., Darragh J., Signaling downstream of p38 in psoriasis. Journal of Investigative Dermatology 2006 126 8 1689 1691 2-s2.0-33746177400 10.1038/sj.jid.5700280 (Pubitemid 44086500)
24. Soegaard-Madsen L., Johansen C., Iversen L., Kragballe K., Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. British Journal of Dermatology 2010 162 6 1216 1223 2-s2.0-77952677598 10.1111/j.1365-2133.2010. 09706.x
25. Funding A. T., Johansen C., Kragballe K., Otkjær K., Jensen U. B., Madsen M. W., Fjording M. S., Finnemann J., Skak-Nielsen T., Paludan S. R., Iversen L., Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. Journal of Investigative Dermatology 2006 126 8 1784 1791 2-s2.0-33746139320 10.1038/sj.jid.5700252 (Pubitemid 44086513)
26. Kjellerup R. B., Johansen C., Kragballe K., Iversen L., The expression of dual-specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin. British Journal of Dermatology 2013 168 2 339 345
27. Andres R. M., Hald A., Johansen C., Kragballe K., Iversen L., Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. Experimental Dermatology 2013 22 5 323 328
28. Hald A., Andres R. M., Salskov-Iversen M. L., Kjellerup R. B., Iversen L., Johansen C., STAT1 expression and activation is increased in lesional psoriatic skin. British Journal of Dermatology 2013 168 2 302 310
29. Mose M., Kang Z., Raaby L., Iversen L., Johansen C., TNFalpha- and IL-17A-mediated S100A8 expression is regulated by p38 MAPK. Experimental Dermatology 2013 22 7 476 481
30. Hau C. S., Kanda N., Noda S., Tatsuta A., Kamata M., Shibata S., Asano Y., Sato S., Watanabe S., Tada Y., Visfatin enhances the production of cathelicidin antimicrobial peptide, human beta-defensin-2, human beta-defensin-3, and S100A7 in human keratinocytes and their orthologs in murine imiquimod-induced psoriatic skin. American Journal of Pathology 2013 182 5 1705 1717
31. Lories R. J. U., Derese I., Luyten F. P., de Vlam K., Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clinical and Experimental Rheumatology 2008 26 1 96 102 2-s2.0-40749113600 (Pubitemid 351385261)
32. Frey S., Derer A., Messbacher M. E., Baeten D. L., Bugatti S., Montecucco C., Schett G., Hueber A. J., The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Annals of the Rheumatic Diseases 2013
33. Kanda N., Shimizu T., Tada Y., Watanabe S., IL-18 enhances IFN- γ -induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. European Journal of Immunology 2007 37 2 338 350 2-s2.0-33947726182 10.1002/eji.200636420 (Pubitemid 46915573)
34. Michalak-Stoma A., Pietrzak A., Szepietowski J. C., Zalewska-Janowska A., Paszkowski T., Chodorowska G., Cytokine network in psoriasis revisited. European Cytokine Network 2011 22 4 160 168 2-s2.0-84857002192 10.1684/ecn.2011.0294
35. Retser E., Schied T., Skryabin B. V., Vogl T., Kanczler J. M., Hamann N., Niehoff A., Hermann S., Eisenblatter M., Wachsmuth L., Pap T., van Lent P., Loser K., Roth J., Zaucke F., Ludwig S., Wixler V., Inducible expression of transgenic human TNFalpha in adult mice develops psoriatic-like arthritis. Arthritis & Rheumatism 2013
36. + T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. Journal of Investigative Dermatology 2013 133 4 973 979
37. Raychaudhuri S. P., Role of IL-17 in psoriasis and psoriatic arthritis. Clinical Reviews in Allergy & Immunology 2013 44 2 183 193
38. Martin D. A., Towne J. E., Kricorian G., Klekotka P., Gudjonsson J. E., Krueger J. G., Russell C. B., The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. Journal of Investigative Dermatology 2013 133 1 17 26
39. Van Belle A. B., De Heusch M., Lemaire M. M., Hendrickx E., Warnier G., Dunussi-Joannopoulos K., Fouser L. A., Renauld J.-C., Dumoutier L., IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. Journal of Immunology 2012 188 1 462 469 2-s2.0-84855367696 10.4049/jimmunol.1102224
40. Botti E., Spallone G., Caruso R., Monteleone G., Chimenti S., Costanzo A., Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target. Current Pharmaceutical Biotechnology 2012 13 10 1861 1867
41. Cauli A., Mathieu A., Th17 and interleukin 23 in the pathogenesis of psoriatic arthritis and spondyloarthritis. Journal of Rheumatology 2012 89 15 18
42. Shibata S., Tada Y., Asano Y., Yanaba K., Sugaya M., Kadono T., Kanda N., Watanabe S., Sato S., IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions. Journal of Investigative Dermatology 2013 133 2 479 488
43. Jensen P., Wiell C., Milting K., Poggenborg R. P., Ostergaard M., Johansen J. S., Skov L., Plasma YKL-40: a potential biomarker for psoriatic arthritis? Journal of the European Academy of Dermatology 2013 27 7 815 819
44. Jin L., Wang G., Keratin 17: a critical player in the pathogenesis of psoriasis. Medicinal Research Reviews 2013
45. Hyder L. A., Gonzalez J., Harden J. L., Johnson-Huang L. M., Zaba L. C., Pierson K. C., Eungdamrong N. J., Lentini T., Gulati N., Fuentes-Duculan J., Suarez-Farinas M., Lowes M. A., TREM-1 as a potential therapeutic target in psoriasis. Journal of Investigative Dermatology 2013 133 7 1742 1751
46. Mitra A., Fallen R. S., Lima H. C., Cytokine-based therapy in psoriasis. Clinical Reviews in Allergy & Immunology 2013 44 2 173 182
47. Laws P. M., Warren R. B., Ustekinumab for the treatment of psoriasis. Expert Review of Clinical Immunology 2011 7 2 155 164 2-s2.0-79953117927 10.1586/eci.11.4
48. Di Cesare A., Di Meglio P., Nestle F. O., The IL-23Th17 axis in the immunopathogenesis of psoriasis. Journal of Investigative Dermatology 2009 129 6 1339 1350 2-s2.0-67349230808 10.1038/jid.2009.59
49. Tsuda K., Yamanaka K., Kondo M., Matsubara K., Sasaki R., Tomimoto H., Gabazza E. C., Mizutani H., Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity. PLoS ONE 2012 7 12 e51819
50. Gan E. Y., Chong W. S., Tey H. L., Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. BioDrugs 2013
51. Piskin G., Tursen U., Sylva-Steenland R. M. R., Bos J. D., Teunissen M. B. M., Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN- γ inducers-IL-12, IL-18 and IL-23. Experimental Dermatology 2004 13 12 764 772 2-s2.0-10344243973 10.1111/j.0906-6705.2004.00246.x (Pubitemid 39625223)
52. Skurkovich B., Skurkovich S., Inhibition of IFN-gamma as a method of treatment of various autoimmune diseases, including skin diseases. 56 Proceedings of the Ernst Schering Research Foundation Workshop 2006 1 27
53. Johnson-Huang L. M., Suárez-Fariñas M., Pierson K. C., Fuentes-Duculan J., Cueto I., Lentini T., Sullivan-Whalen M., Gilleaudeau P., Krueger J. G., Haider A. S., Lowes M. A., A single intradermal injection of IFN- γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. Journal of Investigative Dermatology 2012 132 4 1177 1187 2-s2.0-84858283022 10.1038/jid.2011.458
54. Behrends J., Renauld J. C., Ehlers S., Holscher C., IL-22 is mainly produced by IFNgamma-secreting cells but is dispensable for host protection against Mycobacterium tuberculosis infection. PLoS ONE 2013 8 2 e57379
55. Di Meglio P., Duarte J. H., CD8 T Cells and IFN-gamma emerge as critical players for psoriasis in a novel model of mouse psoriasiform skin inflammation. Journal of Investigative Dermatology 2013 133 4 871 874
56. McKenzie R. C., Sabin E., Szepietowski J. C., Gracie J. A., Forsey R. J., Howie S., Letter to the editor. European Journal of Dermatology 2003 13 3 315 316 2-s2.0-0141499310 (Pubitemid 36683452)
57. McKenzie R. C., Sabin E., Aberrant signalling and transcription factor activation as an explanation for the defective growth control and differentiation of keratinocytes in psoriasis: a hypothesis. Experimental Dermatology 2003 12 4 337 345 2-s2.0-0041464828 10.1034/j.1600-0625.2003.00100.x (Pubitemid 37006279)
58. Haase I., Hobbs R. M., Romero M. R., Broad S., Watt F. M., A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis. Journal of Clinical Investigation 2001 108 4 527 536 2-s2.0-0034883588 10.1172/JCI200112153 (Pubitemid 32777732)
59. Takahashi H., Ibe M., Nakamura S., Ishida-Yamamoto A., Hashimoto Y., Iizuka H., Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. Journal of Dermatological Science 2002 30 2 94 99 2-s2.0-0036876857 10.1016/S0923-1811(02)00064-6 (Pubitemid 36159019)
60. Kyriakis J. M., Avruch J., Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiological Reviews 2012 92 2 689 737 2-s2.0-84860165740 10.1152/physrev.00028.2011
61. Takahashi H., Manabe A., Ishida-Yamamoto A., Hashimoto Y., Iizuka H., Aberrant expression of apoptosis-related molecules in psoriatic epidermis. Journal of Dermatological Science 2002 28 3 187 197 2-s2.0-0036127633 10.1016/S0923-1811(01)00162-1 (Pubitemid 34242653)
62. Mavropoulos A., Orfanidou T., Liaskos C., Smyk D. S., Billinis C., Blank M., Rigopoulou E. I., Bogdanos D. P., p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: lessons to learn from ANCA vasculitis and pemphigus vulgaris. Autoimmunity Reviews 2012
63. Mavropoulos A., Sully G., Cope A. P., Clark A. R., Stabilization of IFN- γ mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells. Blood 2005 105 1 282 288 2-s2.0-11144244014 10.1182/blood-2004-07-2782 (Pubitemid 40053094)
64. Anderson P., Phillips K., Stoecklin G., Kedersha N., Post-transcriptional regulation of proinflammatory proteins. Journal of Leukocyte Biology 2004 76 1 42 47 2-s2.0-1942512174 10.1189/jlb.1103536 (Pubitemid 38857170)
65. Brook M., Sully G., Clark A. R., Saklatvala J., Regulation of tumour necrosis factor α mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Letters 2000 483 1 57 61 2-s2.0-0034644837 10.1016/S0014-5793(00)02084-6
66. Saklatvala J., The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Current Opinion in Pharmacology 2004 4 4 372 377 2-s2.0-3342918498 10.1016/j.coph.2004.03.009 (Pubitemid 38987064)
67. Schett G., Zwerina J., Firestein G., The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 7 909 916 2-s2.0-46849108130 10.1136/ard.2007.074278 (Pubitemid 351956650)
68. Sweeney S. E., The as-yet unfulfilled promise of p38 MAPK inhibitors. Nature Reviews 2009 5 9 475 477 2-s2.0-70350512823 10.1038/nrrheum.2009.171
69. Coulthard L. R., White D. E., Jones D. L., McDermott M. F., Burchill S. A., p38MAPK: stress responses from molecular mechanisms to therapeutics. Trends in Molecular Medicine 2009 15 8 369 379 2-s2.0-68649090472 10.1016/j.molmed. 2009.06.005
70. Abraham S. M., Clark A. R., Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochemical Society Transactions 2006 34 6 1018 1023 2-s2.0-34248679869 10.1042/BST0341018 (Pubitemid 46768980)
71. Clark A. R., MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? Journal of Endocrinology 2003 178 1 5 12 2-s2.0-0041669330 10.1677/joe.0.1780005 (Pubitemid 36927003)
72. Johansen C., Funding A. T., Otkjaer K., Kragballe K., Jensen U. B., Madsen M., Binderup L., Skak-Nielsen T., Fjording M. S., Iversen L., Protein expression of TNF- α in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. Journal of Immunology 2006 176 3 1431 1438 2-s2.0-31144468296 (Pubitemid 43134285)
73. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., Volk H.-D., Gaestel M., MAPKAP kinase 2 is essential for LPS-induced TNF- α biosynthesis. Nature Cell Biology 1999 1 2 94 97 2-s2.0-0033145354 (Pubitemid 129501950)
74. Hegen M., Gaestel M., Nickerson-Nutter C. L., Lin L.-L., Telliez J.-B., MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. Journal of Immunology 2006 177 3 1913 1917 2-s2.0-33746214777 (Pubitemid 44092531)
75. Duraisamy S., Bajpai M., Bughani U., Dastidar S. G., Ray A., Chopra P., MK2: a novel molecular target for anti-inflammatory therapy. Expert Opinion on Therapeutic Targets 2008 12 8 921 936 2-s2.0-48449083636 10.1517/14728222.12.8. 921
76. Gaestel M., Kotlyarov A., Kracht M., Targeting innate immunity protein kinase signalling in inflammation. Nature Reviews Drug Discovery 2009 8 6 480 499 2-s2.0-66749134594 10.1038/nrd2829
77. Funding A. T., Johansen C., Kragballe K., Iversen L., Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. Journal of Investigative Dermatology 2007 127 8 2012 2019 2-s2.0-34447534298 10.1038/sj.jid.5700821 (Pubitemid 47075375)
78. Gesser B., Johansen C., Rasmussen M. K., Funding A. T., Otkjaer K., Kjellerup R. B., Kragballe K., Iversen L., Dimethylfumarate specifically inhibits the Mitogen and Stress-Activated Kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. Journal of Investigative Dermatology 2007 127 9 2129 2137 2-s2.0-34547890303 10.1038/sj.jid.5700859 (Pubitemid 47258496)
79. Ikewaki N., Inoko H., A very late activating antigen- α 4 (CD49d) monoclonal antibody, BU49 induces phosphorylation of a cAMP response element-binding protein (CREB), resulting in induction of homotypic cell aggregation and enhancement of interleukin-8 (IL-8) production. Microbiology and Immunology 2002 46 10 685 695 2-s2.0-0036035325 (Pubitemid 35238848)
80. Dauletbaev N., Eklove D., Mawji N., Iskandar M., Di Marco S., Gallouzi I.-E., Lands L. C., Down-regulation of cytokine-induced interleukin-8 requires inhibition of p38 Mitogen-activated Protein Kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms. Journal of Biological Chemistry 2011 286 18 15998 16007 2-s2.0-79955513515 10.1074/jbc.M110.205724
81. Johansen C., Vinter H., Soegaard-Madsen L., Olsen L. R., Steiniche T., Iversen L., Kragballe K., Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNF α therapy. British Journal of Dermatology 2010 163 6 1194 1204 2-s2.0-78649668321 10.1111/j.1365-2133.2010.10036.x
82. Guan Z., Buckman S. Y., Pentland A. P., Templeton D. J., Morrison A. R., Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway. Journal of Biological Chemistry 1998 273 21 12901 12908 2-s2.0-0032557678 10.1074/jbc.273.21.12901 (Pubitemid 28246849)
83. Celis R., Planell N., Fernandez-Sueiro J. L., Sanmarti R., Ramirez J., Gonzalez-Alvaro I., Pablos J. L., Canete J. D., Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Research & Therapy 2012 R93 2-s2.0-84860222506 10.1186/ar3817
84. Candia L., Marquez J., Hernandez C., Zea A. H., Espinoza L. R., Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? Journal of Rheumatology 2007 34 2 374 379 2-s2.0-33846942595
85. Amital H., Barak V., Winkler R. E., Rubinow A., Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Annals of the New York Academy of Sciences 2007 1110 649 660 2-s2.0-35748951619 10.1196/annals.1423.068 (Pubitemid 350043054)
86. Cordiali-Fei P., Ardigò M., Mastroianni A., Giuliani A., D'Agosto G., Bordignon V., Trento E., Vento A., Berardesca E., Serum cytokines and bioumoral immunological characterization of psoriatic patients in long term etanercept treatment. International Journal of Immunopathology and Pharmacology 2008 21 3 643 649 2-s2.0-53749101805
87. de Vlam K., Lories R. J. U., Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology 2006 45 3 321 324 2-s2.0-33644861049 10.1093/rheumatology/kei153 (Pubitemid 43372848)
88. Danning C. L., Illei G. G., Hitchon C., Greer M. R., Boumpas D. T., McInnes I. B., Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis & Rheumatism 2000 43 6 1244 1256 (Pubitemid 30416309)
89. Zenz R., Eferl R., Kenner L., Florin L., Hummerich L., Mehic D., Scheuch H., Angel P., Tschachler E., Wagner E. F., Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005 437 7057 369 375 2-s2.0-25144497098 10.1038/nature03963 (Pubitemid 41613493)
90. Batliwalla F. M., Li W., Ritchlin C. T., Xiao X., Brenner M., Laragione T., Shao T., Durham R., Kemshetti S., Schwarz E., Coe R., Kern M., Baechler E. C., Behrens T. W., Gregersen P. K., Gulko P. S., Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Molecular Medicine 2005 11 1-12 21 29 2-s2.0-33646507867 10.2119/2006-00003.Gulko
91. Bowcock A. M., Shannon W., Du F., Duncan J., Cao K., Aftergut K., Catier J., Fernandez-Vina M. A., Menter A., Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Human Molecular Genetics 2001 10 17 1793 1805 2-s2.0-0035880456 (Pubitemid 32899097)
92. Quekenborn-Trinquet V., Fogel P., Aldana-Jammayrac O., Ancian P., Demarchez M., Rossio P., Richards H. L., Kirby B., Nguyen C., Voegel J. J., Griffiths C. E. M., Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity. British Journal of Dermatology 2005 152 3 489 504 2-s2.0-20244378241 10.1111/j.1365-2133.2005.06384.x (Pubitemid 40547123)
93. Koczan D., Guthke R., Thiesen H.-J., Ibrahim S. M., Kundt G., Krentz H., Gross G., Kunz M., Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. European Journal of Dermatology 2005 15 4 251 257 2-s2.0-22544480310 (Pubitemid 41020851)
94. Mavropoulos A., Smyk D., Rigopoulou E. I., Bogdanos D. P., Human peripheral blood mononuclear cell culture for flow cytometric analysis of phosphorylated mitogen-activated protein kinases. Methods in Molecular Biology 2012 806 275 285 2-s2.0-82355165004 10.1007/978-1-61779-367-7-19
95. Krutzik P. O., Irish J. M., Nolan G. P., Perez O. D., Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clinical Immunology 2004 110 3 206 221 2-s2.0-1642463417 10.1016/j.clim.2003.11.009 (Pubitemid 38402001)
96. Montag D. T., Lotze M. T., Rapid flow cytometric measurement of cytokine-induced phosphorylation pathways [CIPP] in human peripheral blood leukocytes. Clinical Immunology 2006 121 2 215 226 2-s2.0-33750032109 10.1016/j.clim.2006.06.013 (Pubitemid 44572973)
97. + T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation. Journal of Investigative Dermatology 2007 127 5 1161 1166 2-s2.0-34247268607 10.1038/sj.jid.5700680 (Pubitemid 46625147)
98. Mavropoulos A., Spyrou E., Rigopoulou E. I., Vergani D., Dalekos G. N., Bogdanos D. P., 1107 Phosphorylation of P38 MAPK is detectable in NKT cells of patients with autoimmune hepatitis in whom it mirrors disease activity. Journal of Hepatology 2010 52 S428
99. Bonish B., Jullien D., Dutronc Y., Huang B. B., Modlin R., Spada F. M., Porcelli S. A., Nickoloff B. J., Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN- γ production by NK-T cells. Journal of Immunology 2000 165 7 4076 4085 2-s2.0-0034292333 (Pubitemid 32057319)
100. Cameron A., Kirby B., Fei W., Griffiths C., Natural killer and natural killer-T cells in psoriasis. Archives of Dermatological Research 2002 294 8 363 369 2-s2.0-0036430093 (Pubitemid 35341029)
101. von Bubnoff D., Andrès E., Hentges F., Bieber T., Michel T., Zimmer J., Natural killer cells in atopic and autoimmune diseases of the skin. Journal of Allergy and Clinical Immunology 2010 125 1-3 60 68 2-s2.0-73349104119 10.1016/j.jaci.2009.11.020
102. Zakka L. R., Fradkov E., Keskin D. B., Tabansky I., Stern J. N. H., Ahmed A. R., The role of natural killer cells in autoimmune blistering diseases. Autoimmunity 2012 45 1 44 54 2-s2.0-84856489327 10.3109/08916934.2011.606446
103. Cameron A. L., Kirby B., Griffiths C. E. M., Circulating natural killer cells in psoriasis. British Journal of Dermatology 2003 149 1 160 164 2-s2.0-0041633632 10.1046/j.1365-2133.2003.05319.x (Pubitemid 36966527)
104. Johansson S., Hall H., Berg L., Hoglund P., NK cells in autoimmune disease. Current Topics in Microbiology and Immunology 2006 298 259 277 (Pubitemid 41491732)
105. Selmi C., Lleo A., Pasini S., Zuin M., Gershwin M. E., Innate immunity and primary biliary cirrhosis. Current Molecular Medicine 2009 9 1 45 51 2-s2.0-62749102863 10.2174/156652409787314525
106. Åkesson C., Uvebrant K., Oderup C., Lynch K., Harris R. A., Lernmark Å., Agardh C.-D., Cilio C. M., Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency. Clinical and Experimental Immunology 2010 161 1 48 56 2-s2.0-77953280169 10.1111/j.1365-2249.2010.04114.x
107. Hervier B., Beziat V., Haroche J., Mathian A., Lebon P., Ghillani-Dalbin P., Musset L., Debré P., Amoura Z., Vieillard V., Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon- γ production in patients with active disease. Arthritis & Rheumatism 2011 63 6 1698 1706 2-s2.0-79958070141 10.1002/art.30313
108. Liao Y. H., Jee S. H., Sheu B. C., Huang Y. L., Tseng M. P., Hsu S. M., Tsai T.-F., Increased expression of the natural killer cell inhibitory receptor CD94/NKG2A and CD158b on circulating and lesional T cells in patients with chronic plaque psoriasis. British Journal of Dermatology 2006 155 2 318 324 2-s2.0-33745912540 10.1111/j.1365-2133.2006.07301.x (Pubitemid 44050564)
109. Fusco C., Guerini F. R., Nocera G., Ventrella G., Caputo D., Valentino M. A., Agliardi C., Gallotti J., Morra V. B., Florio C., Clerici M., Lombardi M. L., KIRs and their HLA ligands in remitting-relapsing multiple sclerosis. Journal of Neuroimmunology 2010 229 1-2 232 237 2-s2.0-78650226799 10.1016/j.jneuroim.2010.08.004
110. Qin H., Wang Z., Du W., Lee W.-H., Wu X., Riggs A. D., Liu C.-P., Killer cell Ig-like receptor (KIR) 3DL1 down-regulation enhances inhibition of type 1 diabetes by autoantigen-specific regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 2011 108 5 2016 2021 2-s2.0-79952140360 10.1073/pnas.1019082108
111. Son S. W., Kim E.-O., Ryu E. S., Kim T.-J., Kim J. N., Choi J. E., Kye Y. C., Lee K.-M., Upregulation of Fas and downregulation of CD94/NKG2A inhibitory receptors on circulating natural killer cells in patients with new-onset psoriasis. The British Journal of Dermatology 2009 161 2 281 288 2-s2.0-73349140522